ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 574,28
-0,77%
Dow Jones
40 211,72
0,53%
DAX
18 489,60
-0,59%
Brent Oil
83,625
-0,85%
Bitcoin
62 547,12
-3,55%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Intellia Therapeutics Inc (NTLA)

  7. Intellia Therapeutics Inc (NTLA) Actualités

NTLA

Intellia Therapeutics (NTLA)

Intellia Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:NTLA
DateHeureSourceTitreSymboleSociété
03/08/202322h13Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NTLAIntellia Therapeutics Inc
03/08/202313h45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NTLAIntellia Therapeutics Inc
03/08/202313h30GlobeNewswire Inc.Intellia Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Recent Company ProgressNASDAQ:NTLAIntellia Therapeutics Inc
02/08/202323h19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
31/07/202322h45Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
27/07/202313h30GlobeNewswire Inc.Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2023 Earnings and Company UpdatesNASDAQ:NTLAIntellia Therapeutics Inc
22/06/202323h53Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NTLAIntellia Therapeutics Inc
21/06/202312h00Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:NTLAIntellia Therapeutics Inc
16/06/202322h14Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:NTLAIntellia Therapeutics Inc
11/06/202314h30GlobeNewswire Inc.Intellia Therapeutics Announces New Positive Clinical Data from Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema (HAE)NASDAQ:NTLAIntellia Therapeutics Inc
05/06/202322h01GlobeNewswire Inc.Intellia Therapeutics Announces Retirement of Jean-François Formela, M.D. From its Board of DirectorsNASDAQ:NTLAIntellia Therapeutics Inc
04/05/202322h15Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:NTLAIntellia Therapeutics Inc
04/05/202313h30GlobeNewswire Inc.Intellia Therapeutics Announces First Quarter 2023 Financial Results and Highlights Recent Company ProgressNASDAQ:NTLAIntellia Therapeutics Inc
01/05/202322h29Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:NTLAIntellia Therapeutics Inc
01/05/202313h30GlobeNewswire Inc.Intellia Therapeutics Releases 2023 Corporate Responsibility Report Highlighting the Advancement of its Environmental, Social & Governance (ESG) PrioritiesNASDAQ:NTLAIntellia Therapeutics Inc
27/04/202313h30GlobeNewswire Inc.Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2023 Earnings and Company UpdatesNASDAQ:NTLAIntellia Therapeutics Inc
18/04/202322h50Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:NTLAIntellia Therapeutics Inc
18/04/202322h24Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:NTLAIntellia Therapeutics Inc
18/04/202322h17Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:NTLAIntellia Therapeutics Inc
17/04/202322h01GlobeNewswire Inc.Intellia Therapeutics Names Bill Chase to its Board of DirectorsNASDAQ:NTLAIntellia Therapeutics Inc
21/03/202313h25Dow Jones NewsIntellia Therapeutics Gets FDA RMAT Designation for NTLA-2002 in Hereditary AngioedemaNASDAQ:NTLAIntellia Therapeutics Inc
21/03/202312h30GlobeNewswire Inc.Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to NTLA-2002 for the Treatment of Hereditary AngioedemaNASDAQ:NTLAIntellia Therapeutics Inc
02/03/202313h00GlobeNewswire Inc.Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for NTLA-2002, an In Vivo CRISPR-Based Investigational Therapy for the Treatment of Hereditary Angioedema (HAE)NASDAQ:NTLAIntellia Therapeutics Inc
23/02/202322h19Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:NTLAIntellia Therapeutics Inc
23/02/202322h11Edgar (US Regulatory)Annual Report (10-k)NASDAQ:NTLAIntellia Therapeutics Inc
23/02/202313h30GlobeNewswire Inc.Intellia Therapeutics Announces Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Company ProgressNASDAQ:NTLAIntellia Therapeutics Inc
16/02/202313h30GlobeNewswire Inc.Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2022 Earnings and Company UpdatesNASDAQ:NTLAIntellia Therapeutics Inc
09/02/202317h48Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:NTLAIntellia Therapeutics Inc
11/01/202313h30GlobeNewswire Inc.Intellia Therapeutics Awarded Innovation Passport in the United Kingdom for NTLA-2002, an Investigational Genome Editing Treatment for Hereditary AngioedemaNASDAQ:NTLAIntellia Therapeutics Inc
05/01/202313h30GlobeNewswire Inc.Intellia Therapeutics Highlights Strategic Priorities and Anticipated 2023 Key MilestonesNASDAQ:NTLAIntellia Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:NTLA

Dernières Valeurs Consultées

BIT
S29255
Societe Generale Effekten
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés